

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (previously presented) A pharmaceutical, cosmetic, dietetic or nutraceutical composition comprising:

a first vasoactive agent;

a second vasoactive agent; and

a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin or  
esculoside,

- the second vasoactive agent comprises at least one compound selected from the group consisting of icarin, icarin derivatives, extracts containing icarin, *Ginkgo biloba* dimeric flavones either in a free form or complexed with phospholipids, and amentoflavone, and

- the third vasoactive agent comprises at least one compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids, and *Centella asiatica* extract in a free form or complexed with phospholipids.

2. (previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is 0.05-2% by weight,

the second vasoactive agent is 0.1-1% by weight, and

the third vasoactive agent is 0.5-2% by weight.

3. (withdrawn) The composition as claimed in claim 1, wherein the icarin derivatives are selected from the group consisting of 7-hydroxyethyl-icarin, 7-ethylamino-icarin, 7-aminoethyl-icarin, 7-hydroxyethyl-3-O-rhamnosyl-icarin, 7-aminoethyl-3-rhamnosyl-icarin, 8-dihydro-icarin and glucosides thereof in 7 and 3, and 7-hydroxyethyl-7-desglucoicarin.

4. (currently amended) The composition as claimed in claim 1, wherein the first vasoactive agent, the second vasoactive agent, and the third vasoactive agent are incorporated into a composition is in a form selected from the group consisting of a cream, a gel, a lotion, and a milk.

5. (canceled)

6. (withdrawn) The composition as claimed in claim 1, wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent comprises 7-hydroxyethyl-7-desgluco-icarin and amentoflavone, and

the third vasoactive agent comprises escin.

7. (withdrawn/previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is esculoside,

the second vasoactive agent comprises icarin and amentoflavone, and

the third vasoactive agent comprises escin.

8. (withdrawn) The composition as claimed in claim 1, wherein,

the first vasoactive agent is Visnadin, and

the second vasoactive agent comprises 7-hydroxyethyl-7-desgluco-icarin and *Gingko biloba* dimers in a free form or complexed with phospholipids.

9. (previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent comprises *Gingko biloba*

dimers complexed with phospholipids, and

the third vasoactive agent comprises escin beta-sitosterol complexed with phospholipids.

10. (withdrawn) The composition as claimed in claim 1, wherein,

the first vasoactive agent is esculoside,

the second vasoactive agent comprises *Gingko biloba* dimers complexed with phospholipids, and

the third vasoactive agent comprises escin beta-sitosterol complexed with phospholipids.

11-12. (canceled)

13. (new) A pharmaceutical, cosmetic, dietetic or nutraceutical composition comprising:

a first vasoactive agent;

a second vasoactive agent; and

a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin,

- the second vasoactive agent comprises at least one compound selected from the group consisting of icarin, icarin derivatives, extracts containing icarin, *Gingko biloba* dimeric

flavones either in a free form or complexed with phospholipids, and amentoflavone, and

- the third vasoactive agent comprises at least one compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids, and *Centella asiatica* extract in a free form or complexed with phospholipids.